UroGen Pharma Receives US Patent Allowance for Zusduri, UGN-103
MT Newswires Live
Jul 15
UroGen Pharma (URGN) said Wednesday it has received a US patent allowance covering methods of treating patients with recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer with Zusduri and investigational candidate UGN-103.
The patent allowance is supported by data from two clinical trials and cover treatment without transurethral resection of a bladder tumor, the company said.
The patent, once issued, is expected to expire in July 2044, UroGen said.
Shares of the company were 1.1% higher in premarket activity Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.